Malaria is a major cause of anaemia in tropical areas. Malaria infection causes haemolysis
of infected and uninfected erythrocytes and bone marrow dyserythropoiesis which …

Primaquine is the only generally available anti-malarial that prevents relapse in vivax and
ovale malaria, and the only potent gametocytocide in falciparum malaria. Primaquine …

Primaquine is the only available antimalarial drug that kills dormant liver stages of
Plasmodium vivax and Plasmodium ovale malarias and therefore prevents their relapse …

Relapses arising from dormant liver-stage Plasmodium vivax parasites (hypnozoites) are a
major cause of vivax malaria. However, in endemic areas, a recurrent blood-stage infection …

Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax
malaria. The mechanism of action and optimal dosing are uncertain. We pooled individual …

The technical genesis and practice of 8-aminoquinoline therapy of latent malaria offer
singular scientific, clinical, and public health insights. The 8-aminoquinolines brought …

Introduction: Relapses are important contributors to illness and morbidity in Plasmodium
vivax and P. ovale infections. Relapse prevention (radical cure) with primaquine is required …

Oxidative agents can cause acute haemolytic anaemia in persons with G6PD deficiency.
Understanding the relationship between G6PD genotype and the phenotypic expression of …

The deployment of artesunate for severe malaria and the artemisinin combination therapies
(ACTs) for uncomplicated malaria has been a major advance in antimalarial therapeutics …

Background Radical cure of Plasmodium vivax malaria with 8-aminoquinolines (primaquine
or tafenoquine) is complicated by haemolysis in individuals with glucose-6-phosphate …